Daniel O鈥橦air, MD; Steven J. Yakubov, MD; Kendra J. Grubb, MD; et al.
free access
has audio
JAMA Cardiol. 2023;8(2):111-119. doi:10.1001/jamacardio.2022.4627
This analysis of pooled data from 2 randomized clinical trials evaluates the 5-year incidence, clinical outcomes, and predictors of hemodynamic structural valve deterioration in patients undergoing self-expanding transcatheter aortic valve implantation or surgery.
-
Podcast:
Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation
Ashwin S. Nathan, MD, MS; Kriyana P. Reddy, BS; Lin Yang, MS; et al.
free access
JAMA Cardiol. 2023;8(2):120-128. doi:10.1001/jamacardio.2022.4457
This cohort study identifies differences in the racial, ethnic, and socioeconomic characteristics of patient populations among candidate sites in the US that did vs did not participate in clinical trials for novel transcatheter valve therapies.
Nicholas A. Marston, MD, MPH; James P. Pirruccello, MD; Giorgio E. M. Melloni, PhD; et al.
free access
JAMA Cardiol. 2023;8(2):130-137. doi:10.1001/jamacardio.2022.4466
This cohort study investigates the clinical utility of a polygenic risk score for coronary artery disease in the decision to begin statin therapy for primary prevention.
-
Editor's Note
Cardiovascular Disease Risk Prediction in Young Adults鈥擳he Next Frontier
Sadiya Sana Khan, MD, MSc; Michael J. Pencina, PhD
JAMA Cardiol
Cullen Soares, MD; Michael Kwok, MSc; Kent-Andrew Boucher, MD; et al.
free access
JAMA Cardiol. 2023;8(2):139-149. doi:10.1001/jamacardio.2022.4873
This systematic review and meta-analysis investigates the performance of HIV-specific and general population cardiovascular disease risk prediction models in people with HIV.
Luis E. Rohde, MD, ScD; André Zimerman, MD, PhD; Muthiah Vaduganathan, MD, MPH; et al.
free access
JAMA Cardiol. 2023;8(2):150-158. doi:10.1001/jamacardio.2022.4427
This parallel-design double-blind trial compares data for patients classified as NYHA class I, II, and III at randomization to assess variation in that classification over time and its association with both objective measures of heart failure severity and long-term prognosis.
Linea C. Trudsø, MSc; Jonas Ghouse, MD, PhD; Gustav Ahlberg, MSc, PhD; et al.
free access
JAMA Cardiol. 2023;8(2):159-166. doi:10.1001/jamacardio.2022.4798
This case-control study investigates the association of PCSK9 variants with cardiac structure, cardiac function, and heart failure in humans.
Ambarish Pandey, MD, MSCS; Dalane W. Kitzman, MD; M. Benjamin Nelson, MS; et al.
free access
JAMA Cardiol. 2023;8(2):167-176. doi:10.1001/jamacardio.2022.4903
This prespecified secondary analysis of the REHAB-HF trial evaluates whether baseline frailty modified the benefits of the physical rehabilitation intervention among older patients with acute decompensated heart failure (HF).